Target intelligence / Profile preview

Inosine Monophosphate Dehydrogenase Type II (IMPDH2)

Target: IMPDH2
Molecular classification: Enzyme, Oxidoreductase

Overview

IMPDH2 is a rate-limiting enzyme in the de novo synthesis of guanine nucleotides, catalyzing the conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP). It plays a significant role in cell proliferation and is upregulated in some neoplasms, contributing to chemoresistance and radioresistance. Therefore, IMPDH2 is considered a potential therapeutic target for cancer treatment.

Mechanism of action

Inhibition of IMPDH2 enzymatic activity

Biological functions

Cell proliferationDNA synthesisRNA synthesisRegulation of guanine nucleotide pool

Disease associations

Cancer

Safety considerations

ChemoresistanceRadioresistance

Interacting drugs

Sanglifehrin A

Beyond the preview

Go deeper on Inosine Monophosphate Dehydrogenase Type II (IMPDH2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inosine Monophosphate Dehydrogenase Type II (IMPDH2).

Explore the full profile